Signore Alberto, Artiko Vera, Conserva Martina, Ferro-Flores Guillermina, Welling Mick M, Jain Sanjay K, Hess Søren, Sathekge Mike
Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy.
Center for Nuclear Medicine, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, 101801 Beograd, Serbia.
J Clin Med. 2020 Jul 25;9(8):2372. doi: 10.3390/jcm9082372.
Bacterial infections are the main cause of patient morbidity and mortality worldwide. Diagnosis can be difficult and delayed as well as the identification of the etiological pathogen, necessary for a tailored antibiotic therapy. Several non-invasive diagnostic procedures are available, all with pros and cons. Molecular nuclear medicine has highly contributed in this field by proposing several different radiopharmaceuticals (antimicrobial peptides, leukocytes, cytokines, antibiotics, sugars, etc.) but none proved to be highly specific for bacteria, although many agents in development look promising. Indeed, factors including the number and strain of bacteria, the infection site, and the host condition, may affect the specificity of the tested radiopharmaceuticals. At the Third European Congress on Infection/Inflammation Imaging, a round table discussion was dedicated to debate the pros and cons of different radiopharmaceuticals for imaging bacteria with the final goal to find a consensus on the most relevant research steps that should be fulfilled when testing a new probe, based on experience and cumulative published evidence.
细菌感染是全球患者发病和死亡的主要原因。诊断可能困难且延迟，病因病原体的鉴定也同样如此，而这对于量身定制抗生素治疗是必要的。有几种非侵入性诊断程序可供使用，各有优缺点。分子核医学通过提供几种不同的放射性药物（抗菌肽、白细胞、细胞因子、抗生素、糖类等）在该领域做出了巨大贡献，但尽管许多正在研发的药物看起来很有前景，但没有一种被证明对细菌具有高度特异性。事实上，包括细菌数量和菌株、感染部位以及宿主状况等因素，可能会影响所测试放射性药物的特异性。在第三届欧洲感染/炎症成像大会上，专门举行了一次圆桌讨论，以辩论不同放射性药物用于细菌成像的优缺点，最终目标是根据经验和已发表的累积证据，就测试新探针时应完成的最相关研究步骤达成共识。
